Theriva presented new clinical data at both the ESMO 2025 Congress and the ASCO 2025 Annual Meeting.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Theriva presented new clinical data at both the ESMO 2025 Congress and the ASCO 2025 Annual Meeting.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
American Society of Clinical Oncology
organization
Nothing else this week.
-
European Society for Medical Oncology
Professional organisation
Related events
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Perspective Therapeutics presented interim clinical data at the ASCO meeting in Las Vegas.
- Bristol-Myers Squibb presented clinical data at the European Society for Medical Oncology (ESMO) Congress in Madrid.
Coverage
Newest first; wire copies grouped- GlobeNewswireTheriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expa